Clinical trial NCT03096340: Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer
Official title: A Phase 1 With Expansion Cohort, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Intravenously Infused IT-141 in Subjects With Recurrent or Refractory Solid Tumors
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Cancer
Neoplasms
Tumors
Refractory Solid Tumors
Recurrent Solid Tumors
Keywords: SN-38
irinotecan
Lead sponsor: Intezyne Technologies, Inc.
Sponsor class: INDUSTRY
First posted: 2017-03-30
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: IT141 is a novel nanoparticle formulation of SN-38, the active metabolite of irinotecan, and is intended to deliver more drug to the tumor with reduced toxicity on normal tissues. The study is designed to determine the maximum tolerated dose (MTD) of IT-141, and to investigate pharmacokinetic (PK) parameters and possible pharmacodynamics (PD) relationships. Patients will also be monitored for any response to therapy.


Eligibility criteria: Inclusion Criteria:

* Must be 18 years of age or older.
* Must be males or non-pregnant females who agree to comply with applicable contraceptive requirements of the protocol.
* Must have a histologically or cytologically confirmed, incurable malignancy, for which further standard treatment is not currently available.
* Must have measurable or evaluable disease during the dose escalation phase (measurable disease is preferred for the expanded cohort after MTD is reached).
* Must have an anticipated survival of at least 12 weeks.
* Must be fully informed regarding their illness and the investigational nature of the study protocol, and must sign an Institutional Review Board (IRB) approved Informed Consent Form (ICF).
* Must be ambulatory, with an Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1.
* Must have adequate organ function, as defined by the following:
* Hematologic: ANC 1.5 x 109/L, Hgb ≥ 9.0 g/dL and platelet count 100 x 109/L (platelet count \> 75 x 109/L if documented evidence of bone marrow involvement).
* Hepatic: Total bilirubin 1.5 x ULN; transaminases ≤ 2.5 x ULN (may be up to 5 x ULN if clearly due to liver metastases); prothrombin time (PT) and partial thromboplastin time (PTT) \< 2 x (ULN).
* Renal: Serum creatinine 1.5 x ULN or creatinine clearance 60 mL/min.
* Must be on stable doses of any drugs affecting hepatic drug metabolism or renal drug excretion (e.g. non-steroidal anti-inflammatory drugs, corticosteroids, barbiturates, diphenylhydantoin, narcotic analgesics, probenecid). Such drugs should not be initiated less than 30 days prior to Baseline/C1D1 or at any time during study participation. Whenever possible, narcotic analgesic doses should be stable within 30 days prior to study entry and during the first cycle of therapy.
* Must be recovered from any reversible side effects of prior therapy (e.g. no major surgery, no antineoplastic or experimental therapy, or no significant radiation therapy to hematopoietic sites within 4 weeks of Baseline/C1D1, and no nitrosoureas or nitrogen mustards within 6 weeks of Baseline/C1D1)
* Must understand and be able, willing, and likely to fully comply with study procedures and restrictions.

Exclusion Criteria:

* Current or recurrent disease that could affect the action or disposition of IT-141, or clinical or laboratory assessments.
* Subjects with UGT1A1\*28 polymorphisms.
* Current or relevant previous history of serious, severe or unstable (acute or progressive) physical or psychiatric illness, including any medical disorder that may require treatment or make the subject unlikely to fully complete the study, or any condition that presents undue risk from the IP or procedures.
* Primary brain tumors or known brain metastasis unless clinically stable and on stable or reducing doses of steroids.
* Frequent vomiting.
* Recent history of unintentional weight loss \> 10% of current body weight in the past 3 months.
* Ongoing radiation therapy, chemotherapy, or hormonal therapy. Point radiation to a site of bone pain will be allowed.
* Current (within 1 week of Screening) or regular use of any medication (including over-the-counter (OTC), herbal or homeopathic preparations) that could improve or worsen the cancer being studied, or could affect the action or disposition of IT-141, or its clinical or laboratory assessment; e.g. Coumadin therapy, due to high competitive protein binding. Subjects taking ANY supplemental IRON, i.e., therapeutic or as part of a multivitamin regimen, are excluded from this study, whether prescribed or self-medicated.
* Concomitant use of a UGT1A1 inhibitor, such as idinavir, atazanavir and sorafenib, throughout the study period.
* Known or suspected intolerance or hypersensitivity to IT-141 or any of the stated ingredients.
* History of alcohol or other substance abuse within the last year.
* History of use of another IP within the last 4 weeks prior to enrollment.
* Female subjects who are pregnant or lactating, including females with a positive pregnancy test at screening.
* Previous enrollment in this study, followed by withdrawal for any reason.
* Known HIV-positive subjects on combination anti-retroviral therapy due to the potential for PK interactions with the study agent.
* Evidence of ischemia or myocardial infarction within the past 6 months, or any significant abnormality on ECG.
* A QTc interval outside of normal. (Normal: \< 450 msec for males and \< 460 msec for females)

Primary outcomes:
measure: Maximum tolerated dose of IT-141 administered once every 2 weeks in patients with refractory solid tumors
timeFrame: 18 months
Secondary outcomes:
measure: Adverse event profiles according to the Common Toxicity Criteria for Adverse Events (CTCAE, ver. 4.03)
timeFrame: 18 months
measure: Objective response rate based on RECIST
timeFrame: 18 months
measure: Area under the plasma concentration versus time curve (AUC) of SN-38 and SN-38G
timeFrame: 18 months
measure: Maximum plasma concentration (Cmax) of SN-38 and SN-38G
timeFrame: 18 months
measure: Time to Cmax (Tmax) of SN-38 and SN-38G
timeFrame: 18 months
measure: Elimination rate constant of SN-38 and SN-38G
timeFrame: 18 months
measure: Terminal half-life (t1/2) of SN-38 and SN-38G
timeFrame: 18 months
measure: Total plasma clearance (CL) of SN-38 and SN-38G
timeFrame: 18 months
measure: Volume of distribution (Vz) of SN-38 and SN-38G
timeFrame: 18 months
Other outcomes:
measure: Overall Survival
timeFrame: 18 months
measure: Progression-free Survival
timeFrame: 18 months
measure: Time to progression
timeFrame: 18 months
measure: Disease Control Rate
timeFrame: 2 years
measure: MRI imaging for biodistribution of IT-141
timeFrame: 18 months
measure: Presence of cfDNA
timeFrame: 2 years
measure: Presence of exosomes
timeFrame: 2 years
Locations:
city: Dallas
country: United States
facility: Mary Crowley Cancer Research Centers - Medical City
state: Texas
city: Seattle
country: United States
facility: Seattle Cancer Care Alliance
state: Washington
Study officials:
affiliation: Mary Crowley Cancer Research Centers - Medical City
name: Minal Barve, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Seattle Cancer Care Alliance
name: Kit Wong, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Bakewell SJ, Carie A, Costich TL, Sethuraman J, Semple JE, Sullivan B, Martinez GV, Dominguez-Viqueira W, Sill KN. Imaging the delivery of drug-loaded, iron-stabilized micelles. Nanomedicine. 2017 May;13(4):1353-1362. doi: 10.1016/j.nano.2017.01.009. Epub 2017 Jan 20.